2. Search Result
Search Result
Results for "

anti-inflammatory efficacies

" in MedChemExpress (MCE) Product Catalog:

71

Inhibitors & Agonists

1

Screening Libraries

3

Peptides

1

Inhibitory Antibodies

16

Natural
Products

3

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-118704
    P-2281

    		mTOR Inflammation/Immunology Cancer
    P-2281 is a mTOR inhibitor with anticancer and anti-inflammatory efficacies. P2281 inhibits mTOR activity in colon cancer cells. P-2281 suppresses Dextran sulfate sodium salt (HY-116282C) (DSS)-induced colitis by inhibiting T cell function and is efficacious in a murine model of human colitis .
    P-2281
  • HY-148940
    Docosahexaenoyl glycerol

    		Cannabinoid Receptor Inflammation/Immunology
    Docosahexaenoyl glycerol is an analog of endocannabinoid, which stimulates the glucose uptake and exhibits anti-inflammatory efficacy .
    Docosahexaenoyl glycerol
  • HY-P1615
    Cenupatide

    		Transmembrane Glycoprotein Cancer
    Cenupatide (UPARANT) is a Urokinase-type plasminogen activator receptor (uPAR) inhibitor. Cenupatide has anti-angiogenic and anti-inflammatory efficacy .
    Cenupatide
  • HY-W803134
    (E/Z)-SIS3 free base

    		TGF-beta/Smad Inflammation/Immunology
    E/Z-SIS3 free base exhibits an inhibitory efficacy against smad3, exhibits an anti-fibrotic and anti-inflammatory effect through a TGF-β/smad3 signaling pathway .
    (E/Z)-SIS3 free base
  • HY-107085
    Talmetacin

    		COX Inflammation/Immunology
    Talmetacin exhibits anti-inflammatory and analgesic efficacy .
    Talmetacin
  • HY-110022
    GW1929 hydrochloride

    		PPAR Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    GW1929 hydrochloride is an orally active peroxisome proliferator-activated receptor-γ (PPARγ) agonist with a pKi of 8.84 for human PPAR-γ, and pEC50s of 8.56 and 8.27 for human PPAR-γ and murine PPAR-γ, respectively. GW1929 hydrochloride has antidiabetic efficacy and neuroprotective potential. GW1929 hydrochloride suppresses neuronal apoptosis and shows anti-inflammatory potential .
    GW1929 hydrochloride
  • HY-169215
    Anti-inflammatory agent 93

    		COX Neurological Disease
    Anti-inflammatory agent 93 (compund 2g) is an imidazole derivative of Schiff base with analgesic and anti-inflammatory activities. Anti-inflammatory agent 93 targets COX-2 receptor and produces 89% analgesic efficacy in mice at 100 mg/kg .
    Anti-inflammatory agent 93
  • HY-106365
    Rofleponide

    		Glucocorticoid Receptor Endocrinology
    Rofleponide is a synthetic glucocorticoid that has a high affinity for rat thymic glucocorticoid receptors and has high anti-inflammatory efficacy in experimental animal models .
    Rofleponide
  • HY-167719
    Dersalazine

    UR-12746 free base

    		 Platelet-activating Factor Receptor (PAFR) Inflammation/Immunology
    Dersalazine (UR-12746 free base) is an inhibitor of platelet-activating factor, exhibiting intestinal anti-inflammatory activity and potential efficacy in treating ulcerative colitis.
    Dersalazine
  • HY-159121
    sEH inhibitor-17

    		Epoxide Hydrolase Neurological Disease Inflammation/Immunology
    sEH inhibitor-17 (compound 4f) is an oral active soluble epoxide hydrolase (sEH) inhibitor with the IC50 of 2.94 nM. sEH inhibitor-17 shows anti-inflammatory efficacy .
    sEH inhibitor-17
  • HY-170489
    Antifungal agent 123

    		Bacterial Fungal Toll-like Receptor (TLR) Infection Inflammation/Immunology
    Antifungal agent 123 (Compound 4b) exhibits good affinity to the oxidoreductase of Staphylococcus aureus or the membrane protein of Candida albicans, exhibits antibacterial and antifungal activities. Antifungal agent 123 scavenges free radical, exhibits antioxidant efficacy. Antifungal agent 123 inhibits the TLR signaling pathway, and exhibits anti-inflammatory efficacy .
    Antifungal agent 123
  • HY-116184
    PF-05387252

    		Endogenous Metabolite Inflammation/Immunology
    PF-05387252 is a potent and selective IRAK4 inhibitor with the activity of inhibiting endogenous TLR signaling pathways. PF-05387252 has shown anti-inflammatory activity in experimental models and may have potential clinical application value in inhibiting psoriasis. Although PF-05387252 and its related compounds have shown anti-inflammatory effects in animal models, their efficacy in inhibiting psoriasis has not yet been verified .
    PF-05387252
  • HY-163271
    XL-126

    		Epigenetic Reader Domain Inflammation/Immunology
    XL-126 (Compound 33) is a potent BD1-selective BET inhibitor, with a Kd of 8.9 nM. XL-126 leads to both the preservation of platelets and potent anti-inflammatory efficacy by BD1 selectivity .
    XL-126
  • HY-N8342
    Rhamnazin

    		VEGFR Inflammation/Immunology Cancer
    Rhamnazin is an orally active inhibitor of VEGFR2 signaling with an IC50 of 4.68 μM against VEGFR2 kinase. Rhamnazin shows potent antiangiogenic activity and antitumor efficacy . Rhamnazin shows antioxidant and anti-inflammatory properties .
    Rhamnazin
  • HY-P10431
    Hc-CATH

    Sea snake cathelicidin

    		 Bacterial Infection Inflammation/Immunology
    Hc-CATH (Sea snake cathelicidin) is an antibacterial peptide with broad-spectrum. Hc-CATH inhibits Shigella dysenteriae and Klebsiella pneumoniae with MIC of 0.16 mM-20.67 mM. Hc-CATH exhibits anti-inflammatory efficacy .
    Hc-CATH
  • HY-118312
    CAY10657

    		NF-κB Inflammation/Immunology
    CAY10657 is an inhibitor for NF-κB pathway. CAY10657 downregulates expressions of proinflammatory cytokine (IL-6) and chemokine (MCP-1), and thus exhibits anti-inflammatory efficacy against meningitis induced by Streptococcus suis .
    CAY10657
  • HY-N0396
    Harpagoside
    2 Publications Verification

    		 COX NO Synthase Inflammation/Immunology Cancer
    Harpagoside can be obtained by Harpagophytum procumbens, which has anti-inflammatory, anti-cancer, protective activity, and efficacy. Harpagoside has an inhibitory effect on COX-1 and COX-2 active, and suppresses NO production. Harpagoside inhibits HepG2 cell lipid polysaccharide, which is a protein that is expressed horizontally and selectively, and has anti-inflammatory and latent pain effects. Harpagoside has the ability to protect the body, and has a degenerative effect on the β-oxidation (Aβ).
    Harpagoside
  • HY-167734
    Pemedolac

    AY-30715

    		 COX Inflammation/Immunology
    Pemedolac (AY-30715) is a potent analgesic with significant pain-relief efficacy against chemically induced and inflammatory pain in animal models. Pemedolac displays a notable separation between analgesic effects and anti-inflammatory activity, achieving effective pain relief at much lower doses than those required for anti-inflammatory or gastric irritant effects. Pemedolac also shows low ulcerogenic potential, indicating a safer profile compared to standard NSAIDs while being utilized for the treatment of neurological, skin, and musculoskeletal disorders.
    Pemedolac
  • HY-107561
    A-943931 hydrochloride

    		Histamine Receptor Inflammation/Immunology
    A-943931 (Compound 10) is a histamine H4 receptor antagonists. A-943931 has improved pharmacotropic and in vivo efficacy in models of pain and inflammation. A-943931 can be used in vivo anti-inflammatory and anti-nociception research .
    A-943931 hydrochloride
  • HY-N12261
    Benastatin B

    		Glutathione S-transferase Bacterial Infection Inflammation/Immunology Cancer
    Benastatin B is an inhibitor for glutathione S-transferase, that inhibits human pi class GST with an IC50 of 1.10 μg/mL. Benastatin B exhibits board-spectrum antibacterial efficacy, inhibits MRSA with MIC 3.1 μg/mL. Benastatin B exhibits anti-inflammatory efficacy through inhibition of IgE mediated β-hexosaminidase release with an IC50 of 79 μg/mL .
    Benastatin B
  • HY-113936
    A-943931

    		Histamine Receptor Neurological Disease Inflammation/Immunology
    A-943931 is a potent and selective histamine H4 receptor (H4R) antagonist with pKi values of 4.6, 3.8 nM for human and rat H4R, respectively. A-943931 shows anti-inflammatory and antinociceptive efficacy .
    A-943931
  • HY-143444
    JAK-IN-20

    		JAK Inflammation/Immunology
    JAK-IN-20 is a potent, pan and orally active JAK inhibitor with an IC50s of 7 nM, 5 nM, 14 nM for JAK1, JAK2, JAK3, respectively. JAK-IN-20 shows excellent pharmacokinetics and displays anti-inflammatory efficacy in vivo .
    JAK-IN-20
  • HY-158417
    KSI-6666

    		LPL Receptor Inflammation/Immunology
    KSI-6666 is an orally active, competitive antagonist for sphingosine 1-phosphate receptor 1 (S1PR1), with an IC50 of 6.4 nM. KSI-6666 exhibits anti-inflammatory efficacy in autoimmune encephalomyelitis model and T cell transfer colitis model .
    KSI-6666
  • HY-138007
    SR-1903

    		ROR PPAR LXR Metabolic Disease Inflammation/Immunology
    SR-1903 is an inverse agonist of RORγ and PPARγ (IC50 of ∼100 nM and 209 nM for RORγ and PPARγ, respectively) and a LXR agonist. SR-1903 exhibits anti-inflammatory and anti-diabetic efficacy in collagen-induced arthritis and diet-induced obesity mouse models .
    SR-1903
  • HY-170409
    BNN27

    		Trk Receptor Apoptosis Neurological Disease Inflammation/Immunology
    BNN27 is the agonist for TrkA receptor and p75NTR receptor, that exhibits neurotrophic and anti-apoptotic effects. BNN27 increases the levels of glutamate, GABA, and glutamine in the rat hippocampus and prefrontal cortex, improves glutamate turnover. BNN27 exhibits neuroprotective efficacy in mouse amyotrophic lateral sclerosis (ALS) model, exhibits anti-inflammatory efficacy in experimental autoimmune encephalomyelitis (EAE) model, exhibits retinal protective efficacy in rat diabete models. BNN27 is blood-brain barrier penetrable .
    BNN27
  • HY-N0396R
    Harpagoside (Standard)

    		Reference Standards COX NO Synthase Inflammation/Immunology
    Harpagoside (Standard) is the analytical standard of Harpagoside. This product is intended for research and analytical applications. Harpagoside can be obtained by Harpagophytum procumbens, which has anti-inflammatory, anti-cancer, protective activity, and efficacy. Harpagoside has an inhibitory effect on COX-1 and COX-2 active, and suppresses NO production. Harpagoside inhibits HepG2 cell lipid polysaccharide, which is a protein that is expressed horizontally and selectively, and has anti-inflammatory and latent pain effects. Harpagoside has the ability to protect the body, and has a degenerative effect on the β-oxidation (Aβ) .
    Harpagoside (Standard)
  • HY-169420
    IL-6-IN-1

    		Interleukin Related Inflammation/Immunology
    IL-6-IN-1 (Compound 22) inhibits the release of IL-6 with an IC50 of 1.065 μM. IL-6-IN-1 exhibits anti-inflammatory efficacy in LPS (HY-D1056)-induced acute lung injury in mouse model .
    IL-6-IN-1
  • HY-110151
    Bengamide B

    		NF-κB Interleukin Related Cancer
    Bengamide B is an inhibitor for NF-κB with an IC50 of 85 nM. Bengamide B inhibits LPS (HY-D1056)-induced expression of TNF-α, IL-6 and MCP-1, exhibits anti-inflammatory activity. Bengamide B exhibits antitumor efficacy (IC50 for HCT-116 is 2 nM) .
    Bengamide B
  • HY-113829
    Valnemulin

    		Antibiotic Bacterial Infection Inflammation/Immunology
    Valnemulin is an orally active broad-spectrum antibiotic against Gram-negative and Gram-positive bacteria, anaerobic bacteria, Mycoplasma, and Spirochetes. Valnemulin ameliorates enteric diseases, acute polyarthritis and enzootic pneumonia in pigs . Valnemulin exhibits anti-inflammatory efficacy against lipopolysaccharide (HY-D1056)-induced lung injury .
    Valnemulin
  • HY-155611
    Cathepsin C-IN-6

    		Cathepsin Inflammation/Immunology
    Cathepsin C-IN-6 (compound 2) is a E-64c-hydrazideas based inhibitor of cathepsin C with anti-inflammatory activity. Cathepsin C-IN-6 inhibts activation of neutrophil elastase，exhibits potential efficacy in inflammatory diseases with high neutrophil load (e.g.，chronic obstructive pulmonary disease) .
    Cathepsin C-IN-6
  • HY-134521
    Diclofenac amide

    		COX Inflammation/Immunology
    Diclofenac amide is a prodrug for Diclofenac sodium (HY-15037). Diclofenac amide is an orally active inhibitor for COX-1/2, that inhibits the production of prostaglandins (PG) and thromboxanes (TX). Diclofenac amide exhibits anti-inflammatory efficacy in Carrageenan (HY-125474)-induced rat paw edema model without causing gastric ulcer (300 μmol/kg) .
    Diclofenac amide
  • HY-168709
    Nrf2 activator 18

    		Keap1-Nrf2 Inflammation/Immunology
    Nrf2 activator 18 (Compound 11a) is an orally active activator for Keap1/Nrf2/HO-1 signaling pathway, that promotes the Nrf2 nuclear translocation, and enhances the antioxidant efficacy. Nrf2 activator 18 inhibits the release of IL-6 with an IC50 of 4.816 μM. Nrf2 activator 18 exhibits anti-inflammatory efficacy in mouse PM2.5-induced lung injury model .
    Nrf2 activator 18
  • HY-P10839
    NBD peptide

    		NF-κB Inflammation/Immunology
    NBD peptide inhibits NF-κB signaling pathway through inhibition of the NEMO-IKK complex combination. NBD peptide exhibits anti-inflammatory efficacy through block of pro-inflammatory cytokines production. NBD peptide exhibits immunosuppressive activity through regulation of immune cells. NBD peptide enhances its transmembrane ability by combining with cell-penetrating peptide HIV-TAT .
    NBD peptide
  • HY-163998
    TLR4-IN-1

    		Toll-like Receptor (TLR) Inflammation/Immunology
    TLR4-IN-1 (compound 3k) inhibits the cell viability of RAW264.7 with an IC50 of 1.02 μM. TLR4-IN-1 inhibits the release of cytokine TNF-α, IL-1β and IL-6, and exhibits anti-inflammatory efficacy in rats rheumatoid arthritis models .
    TLR4-IN-1
  • HY-P991289
    EBI-031

    		Interleukin Related Inflammation/Immunology
    EBI-031 is a humanized antibody inhibitor targeting IL-6. EBI-031 is a nonsteroidal anti-inflammatory inhibitor. EBI-031 has superior biological efficacy in the management of ocular diseases, such as non-infectious uveitis (NIU) and retinal vascular diseases, and other disease including non-uveitic macular edema and diabetic macular edema .
    EBI-031
  • HY-W775346
    Delta8-THC acetate

    Δ8-THC acetate; Delta8-tetrahydrocannabinol

    		 Cannabinoid Receptor Neurological Disease Inflammation/Immunology
    Delta8-THC acetate (Delta8-tetrahydrocannabinol) is a psychoactive phytocannabinoid, that binds to cannabinoid receptor 1 (CB1 receptor), and exhibits anti-nausea, appetite-stimulating, and anti-inflammatory activities. Delta8-THC acetate exhibits probably neuroprotective efficacy and can be used in anti-anxiety and antidepressant research .
    Delta8-THC acetate
  • HY-118756
    Anirolac

    RS37326

    		 Endogenous Metabolite Inflammation/Immunology
    Anirolac (RS37326) is a nonsteroidal anti-inflammatory agent with analgesic activity. Anirolac showed analgesic efficacy comparable to that of naproxen in suppressing moderate or severe postpartum uterine pain. Anirolac induced significantly higher analgesia scores than placebo within 6 hours, especially at the 100 mg dose. Anirolac effectively relieved pain and showed a stronger analgesic effect than placebo in every assessment .
    Anirolac
  • HY-168734
    CB2 receptor agonist 9

    		Cannabinoid Receptor Inflammation/Immunology
    CB2 receptor agonist 9 (Compound 33) is an orally active agonist for cannabinoid receptor 2 (CB2 receptor) with an EC50 of 16.2 nM. CB2 receptor agonist 9 inhibits the expression of TNF-α, IL-1β and IL-6, exhibits anti-inflammatory efficacy in DDS (HY-116282)-induced mouse acute colitis model .
    CB2 receptor agonist 9
  • HY-125527A
    17(R)-Resolvin D1

    17(R)-RvD1; AT-RvD1

    		 TRP Channel Inflammation/Immunology
    17R-Resolvin D1 (17R-RvD1; AT-RvD1) is an aspirin-triggered epimer of Resolvin D1, which exhibits anti-inflammatory activity in mice and human PMNs cells . 17R-Resolvin D1 specificially inhibits TRPV3 with an IC50 of 398 nM and exhibits peripheral anti-nociceptive efficacy .
    17(R)-Resolvin D1
  • HY-128171
    Diflapolin
    1 Publications Verification

    		 FLAP Epoxide Hydrolase Inflammation/Immunology
    Diflapolin is a highly active dual 5-lipoxygenase-activating protein (FLAP)/soluble epoxide hydrolase (sEH) inhibitor with marked anti-inflammatory efficacy and high target selectivity. Diflapolin inhibits 5-LOX product formation in intact human monocytes and neutrophils with IC50s?of? 30 and 170?nM, respectively, and suppressed the activity of isolated sEH (IC50=20?nM) .
    Diflapolin
  • HY-120471
    AM-0687

    		PI3K Inflammation/Immunology
    AM-0687 is a selective inhibitor for PI3Kδ with an IC50 of 2.9 nM. AM-0687 decreases the levels of IgG and IgM specific antibodies, inhibits the anti-IgM/CD40L-induced proliferation of human B cell (IC50=0.8 nM) and the phosphorylation of AKT (IC50=0.7 nM), and exhibits anti-inflammatory efficacy .
    AM-0687
  • HY-B1671
    (+)-Kavain

    		GABA Receptor Sodium Channel Calcium Channel Neurological Disease Metabolic Disease
    (+)-Kavain, a main kavalactone extracted from Piper methysticum, has anticonvulsive properties, attenuating vascular smooth muscle contraction through interactions with voltage-dependent Na + and Ca 2+ channels . (+)-Kavain is shown to bind at the α4β2δ GABAA receptor and potentiate GABA efficacy . (+)-Kavain is used as a treatment for inflammatory diseases, its anti-inflammatory action has been widely studied .
    (+)-Kavain
  • HY-N2453
    Convallatoxin

    		PPAR NF-κB P-glycoprotein Inflammation/Immunology Cancer
    Convallatoxin is a cardiac glycoside isolated from Adonis amurensis Regel et Radde. Convallatoxin ameliorates colitic inflammation via activation of PPARγ and suppression of NF-κB. Convallatoxin is a P-glycoprotein (P-gp) substrate and recognized Val982 as an important amino acid involved in its transport. Convallatoxin is an enhancer of ligand-induced MOR endocytosis with high potency and efficacy. Anti-inflammatory and anti-proliferative properties .
    Convallatoxin
  • HY-147276
    Izuforant

    JW1601

    		 Histamine Receptor Inflammation/Immunology
    Izuforant (JW1601) (Compound 24) is an orally active histamine H4 receptor (H4R) antagonist with an IC50 of 36 nM against human H4R. Izuforant also shows binding affinity of human serotonin 3 receptor (h5-HT3R) with an IC50 of 9.1 μM. Izuforant exhibits strong anti-pruritic and anti-inflammatory efficacies .
    Izuforant
  • HY-135646
    Eleutheroside B1

    		Influenza Virus Infection Inflammation/Immunology
    Eleutheroside B1, a coumarin compound, has a wide spectrum of anti-human influenza virus efficacy, with an IC50 value of 64-125 µg/ml. Eleutheroside B1 mediates its anti-influenza activity through POLR2A and N-glycosylation. Eleutheroside B1 inhibits the mRNA expression of several chemokine genes and the influenza nucleoprotein (NP) gene, and exhibits low cytotoxicity. Antiviral and anti-inflammatory activities .
    Eleutheroside B1
  • HY-155458
    HYDAMTIQ

    		PARP Inflammation/Immunology Cancer
    HYDAMTIQ is a PARP-1/2 inhibitor (IC50: 29-38 nM) with anticancer, anti-inflammatory, and ischemic protective effects. HYDAMTIQ inhibits pulmonary PARP activity, is effective against allergen-induced cough and dyspnea, and inhibits bronchial hyperresponsiveness to methacholine. HYDAMTIQ has broad-spectrum tumor suppressor effects, including ovarian and breast cancers, prostate and pancreatic tumors, and glioblastoma multiforme. HYDAMTIQ has demonstrated in vivo efficacy in animal models of cerebral ischemia, asthma, cancer, and more .
    HYDAMTIQ
  • HY-N0894A
    (3R,5R)-Octahydrocurcumin

    (3R,5R)-Hexahydrobisdemethoxycurcumin

    		 Drug Metabolite Neurological Disease Inflammation/Immunology
    (3R,5R)-Octahydrocurcumin (Compound 7) is gut microbial metabolite of Curcumin (HY-N0005). (3R,5R)-Octahydrocurcumin exhibits neuroprotective efficacy against Aβ25-35-induced cell damage in SH-SY5Y, and anti-inflammatory activity against LPS-stimulated mouse microglial BV-2 .
    (3R,5R)-Octahydrocurcumin
  • HY-170527
    Anticancer agent 260

    		Reactive Oxygen Species (ROS) Neurological Disease Inflammation/Immunology Cancer
    Anticancer agent 260 (Compound 3g/4d) is an orally active anticancer agent, that inhibits the proliferation of cancer cell HCT-116, MIA-PaCa2 and MDA-MB231 with IC50s of 98.7, 81.0, and 77.2 µg/mL, respectively. Anticancer agent 260 exhibits promotes ulcer formation and lipid peroxidation, anti-inflammatory and analgesic efficacy .
    Anticancer agent 260
  • HY-W747879
    Diclofenac Amide-13C6

    		Isotope-Labeled Compounds COX Inflammation/Immunology
    Diclofenac Amide- 13C6 is the 13C-labeled Diclofenac amide (HY-134521). Diclofenac amide is a prodrug for Diclofenac sodium (HY-15037). Diclofenac amide is an orally active inhibitor for COX-1/2, that inhibits the production of prostaglandins (PG) and thromboxanes (TX). Diclofenac amide exhibits anti-inflammatory efficacy in Carrageenan (HY-125474)-induced rat paw edema model without causing gastric ulcer (300 μmol/kg) .
    Diclofenac Amide-13C6
  • HY-B1671R
    (+)-Kavain (Standard)

    		Reference Standards GABA Receptor Sodium Channel Calcium Channel Neurological Disease Metabolic Disease
    (+)-Kavain (Standard) is the analytical standard of (+)-Kavain. This product is intended for research and analytical applications. (+)-Kavain, a main kavalactone extracted from Piper methysticum, has anticonvulsive properties, attenuating vascular smooth muscle contraction through interactions with voltage-dependent Na+ and Ca2+ channels . (+)-Kavain is shown to bind at the α4β2δ GABAA receptor and potentiate GABA efficacy . (+)-Kavain is used as a treatment for inflammatory diseases, its anti-inflammatory action has been widely studied .
    (+)-Kavain (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: